The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

POSTER
Lipid and Glycemic Profile of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
Author(s):

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Alexandra Lovett, MD,2 Christoph U. Correll, MD3-6

1Stanford University, Stanford, CA; 2Alkermes, Inc., Waltham, MA; 3The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY; 4Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY; 5Charité Universitätsmedizin Berlin, Department of Child and Adolescent Psychiatry, Berlin, Germany; 6German Center for Mental Health (DZPG), partner site Berlin, Germany

Content available until 05/27/2028
Listen to Audio Abstract
0:00 0:00